Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00149383 |
Recruitment Status :
Completed
First Posted : September 8, 2005
Last Update Posted : April 13, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Falciparum Malaria | Drug: Rosiglitazone Drug: Placebo | Phase 1 Phase 2 |
Study Rationale: Evidence suggests that if PPAR-RXR agonists (such as rosiglitazone) are used as adjunctive therapy in P. falciparum malaria infections they may increase phagocytic clearance of P. falciparum malaria, modulate deleterious inflammatory responses and decrease sequestration of malaria parasites in vital organs. They may therefore represent a novel immunomodulatory treatment approach for P. falciparum malaria.
Study Objectives: 1) To examine the in vivo effect of rosiglitazone on the rapidity of clearance of P. falciparum parasitemia and fever in patients with non-severe P. falciparum infections 2) To assess the safety and tolerability of adjunctive rosiglitazone treatment in non-severe cases of P. falciparum infection.
Primary Outcomes: Time to clearance of P. falciparum parasitemia
Study Design: Randomized double blind placebo-controlled trial.
Intervention: Standard antimalarial treatment (atovaquone/proguanil) to all patients combined with adjuvant rosiglitazone treatment (8mg per day) or placebo.
Setting: Hospital for Tropical Diseases at Mahidol University, Thailand.
Participants: 140 patients with non-severe P. falciparum infection.
Follow-up: 28 days
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 140 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-blind, Placebo-controlled Trial of Rosiglitazone as Adjunctive Therapy for P.Falciparum Infection |
Study Start Date : | December 2004 |
Actual Primary Completion Date : | November 2005 |
Actual Study Completion Date : | January 2006 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: 2 |
Drug: Placebo |
Experimental: 1 |
Drug: Rosiglitazone |
- Time to clearance (in hours) of parasitemia from blood is recorded [ Time Frame: 5 days ]
- Time to resolution of fever (in hours) [ Time Frame: 5 days ]
- AST/ALT levels (U/L) [ Time Frame: 2 days ]
- Capillary blood glucose (mmol/L) [ Time Frame: 2 days ]
- Need for ICU admission [ Time Frame: 5 days ]
- Tolerability of study drug/placebo as assessed by patient log [ Time Frame: 5 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Microscopically confirmed P.falciparum infection
- Age >18 years
- Able to tolerate oral therapy
- Able to give informed consent
Exclusion Criteria:
- Fulfillment of WHO criteria for severe/cerebral malaria
- Prior treatment with any thiazolidinedione
- Allergy to rosiglitazone
- History of diabetes mellitus
- History of severe/decompensated liver disease
- ALT level >2.5 times normal
- Current treatment for congestive heart failure
- Pregnancy or breastfeeding

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00149383
Thailand | |
Faculty of Tropical Medicine, Mahidol University | |
Bangkok, Thailand, 10400 |
Principal Investigator: | Kevin C Kain, MD, FRCPC | Faculty of Medicine, University of Toronto; McLaughlin-Rotman Center for Global Health, Toronto |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Mahidol University |
ClinicalTrials.gov Identifier: | NCT00149383 |
Other Study ID Numbers: |
033-2004 |
First Posted: | September 8, 2005 Key Record Dates |
Last Update Posted: | April 13, 2015 |
Last Verified: | April 2015 |
randomized controlled trial malaria Plasmodium falciparum |
thiazolidinediones rosiglitazone atovaquone-proguanil |
Malaria Malaria, Falciparum Protozoan Infections Parasitic Diseases Infections |
Vector Borne Diseases Rosiglitazone Hypoglycemic Agents Physiological Effects of Drugs |